| Non-Alcoholic Fatty Liver Disease |
1 |
1 |
| Biliary Disease |
0 |
1 |
| Metabolic Syndrome |
0 |
0.86 |
| Liver |
0 |
0.83 |
| Hepatocellular Carcinoma |
0 |
0.66 |
| Liver Disease |
0 |
0.66 |
| Fatty Liver |
0 |
0.62 |
| Hepatic Fibrosis |
0 |
0.62 |
| End-Stage Liver Disease |
0 |
0.57 |
| Liver Transplantation |
0 |
0.55 |
| Model for End-Stage Liver Disease |
0 |
0.52 |
| Histology |
0 |
0.39 |
| Biomarker |
0 |
0.22 |
| Cirrhosis |
0 |
0.22 |
| Cancer |
0 |
0.11 |
| Europe |
0 |
0.11 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Ascites |
0 |
0.06 |
| Biopsy |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Cyclooxygenase (COX) |
0 |
0.06 |
| Medical Innovations |
0 |
0.06 |
| Meta-Analysis |
0 |
0.06 |
| Nonalcoholic Steatohepatitis |
0 |
0.06 |
| Transplantation |
0 |
0.06 |
| Ultrasonography |
0 |
0.06 |
| Type 2 Diabetes Mellitus |
0 |
0.05 |